Blue Chip Partners’s VanEck Pharmaceutical ETF PPH Stock Holding History

Blue Chip Partners’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$369K	Sell	3,376 -513	-13%	-$53.1K	0.02%	141
2026 Q1	$404K	Buy	3,889 +411	+12%	+$43.8K	0.03%	128
2025 Q4	$359K	Sell	3,478 -1,499	-30%	-$146K	0.03%	133
2025 Q3	$450K	Buy	+4,977	New	+$436K	0.03%	110
2025 Q1	–	Sell	-24,786	Closed	-$2.14M	–	167
2024 Q4	$2.14M	Buy	+24,786	New	+$2.24M	0.18%	61

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Blue Chip Partners's PPH Position: Q2 2026 in Review

Blue Chip Partners reduced its VanEck Pharmaceutical ETF (PPH) stake by 13% in Q2 2026, selling an estimated $53.1K and leaving 3,376 shares worth $369K. The position accounts for 0.02% of the portfolio, ranked #141.

Blue Chip Partners first reported a position in PPH in Q4 2024 and has held it in 5 quarters since. The position peaked at $2.14M in Q4 2024. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Blue Chip Partners held 3,376 shares of VanEck Pharmaceutical ETF worth $369K as of Q2 2026.
Blue Chip Partners sold 513 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $53.1K.
VanEck Pharmaceutical ETF made up 0.02% of Blue Chip Partners's portfolio in Q2 2026, its #141 holding.
Blue Chip Partners first reported a position in VanEck Pharmaceutical ETF in Q4 2024 and has held it in 5 quarters since.
Blue Chip Partners's VanEck Pharmaceutical ETF position peaked at $2.14M in Q4 2024.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Blue Chip Partners's 13F filing for Q2 2026, filed 14 Aug 2026.